Matthew C. Jarvis

Matthew C. Jarvis

Auto-generated profile, based on publicly available information

Matthew C. Jarvis

Masonic Cancer Center, University of Minnesota, Minneapolis, MN 2

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ELEmily K. Law
Emily K. Law
RLRena Levin-Klein
Rena Levin-Klein
MJMatthew C. Jarvis
Matthew C. Jarvis
HKHyoung Kim
Hyoung Kim
PAProkopios P. Argyris
Prokopios P. Argyris
RHReuben Harris
Reuben Harris
The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the second largest source of mutation in cancer. This mutational process may be a causal driver or inconsequential passenger to the overall tumor phenotype. We show that human APOBEC3A expression in murine colon and liver tissues increases tumorigenesis. All other APOBEC3 family members, including APOBEC3B, fail to promote liver tumor formation. Tumor DNA sequences from APOBEC3A-expressing animals display hallmark APOBEC signature mutations in TCA/T motifs. Bioinformatic comparisons of the observed APOBEC3A mutation signature in murine tumors, previously reported APOBEC3A and APOBEC3B mutation signatures in yeast, and reanalyzed APOBEC mutation signatures in human tumor datasets support cause-and-effect relationships for APOBEC3A-catalyzed deamination and mutagenesis in driving multiple human cancers.

12 November 2018 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
ACAdam Z. Cheng
Adam Z. Cheng
JYJaime Yockteng-Melgar
Jaime Yockteng-Melgar
MJMatthew C. Jarvis
Matthew C. Jarvis
NMNatasha Malik-Soni
Natasha Malik-Soni
IBIvan Borozan
Ivan Borozan
RHReuben Harris
Reuben Harris
The apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like (APOBEC) family of single-stranded DNA (ssDNA) cytosine deaminases provides innate immunity against virus and transposon replication1,2,3,4. A well-studied mechanism is APOBEC3G restriction of human immunodeficiency virus type 1, which is counteracted by a virus-encoded degradation mechanism1,2,3,4. Accordingly, most work has focused on retroviruses with obligate ssDNA replication intermediates and it is unclear whether large double-stranded DNA (dsDNA) viruses may be similarly susceptible to restriction. Here, we show that the large dsDNA herpesvirus Epstein–Barr virus (EBV), which is the causative agent of infectious mononucleosis and multiple cancers5, utilizes a two-pronged approach to counteract restriction by APOBEC3B. Proteomics studies and immunoprecipitation experiments showed that the ribonucleotide reductase large subunit of EBV, BORF26,7, binds APOBEC3B. Mutagenesis mapped the interaction to the APOBEC3B catalytic domain, and biochemical studies demonstrated that BORF2 stoichiometrically inhibits APOBEC3B DNA cytosine deaminase activity. BORF2 also caused a dramatic relocalization of nuclear APOBEC3B to perinuclear bodies. On lytic reactivation, BORF2-null viruses were susceptible to APOBEC3B-mediated deamination as evidenced by lower viral titres, lower infectivity and hypermutation. The Kaposi’s sarcoma-associated herpesvirus homologue, ORF61, also bound APOBEC3B and mediated relocalization. These data support a model where the genomic integrity of human γ-herpesviruses is maintained by active neutralization of the antiviral enzyme APOBEC3B.

1 January 2016 in Preventive Veterinary Medicine
Verified
Journal Article
Open access
MJMatthew C. Jarvis
Matthew C. Jarvis
HLHam Ching Lam
Ham Ching Lam
YZYan Zhang
Yan Zhang
Leyi WangLeyi Wang
Leyi Wang
RHRichard A. Hesse
Richard A. Hesse
DMDouglas Marthaler
Douglas Marthaler
Porcine epidemic diarrhea virus (PEDV) has caused severe economic losses both recently in the United States (US) and historically throughout Europe and Asia. Traditionally, analysis of the spike gene has been used to determine phylogenetic relationships between PEDV strains. We determined the complete genomes of 93 PEDV field samples from US swine and analyzed the data in conjunction with complete genome sequences available from GenBank (n=126) to determine the most variable genomic areas. Our results indicate high levels of variation within the ORF1 and spike regions while the C-terminal domains of structural genes were highly conserved. Analysis of the Receptor Binding Domains in the spike gene revealed a limited number of amino acid substitutions in US strains compared to Asian strains. Phylogenetic analysis of the complete genome sequence data revealed high rates of recombination, resulting in differing evolutionary patterns in phylogenies inferred for the spike region versus whole genomes. These finding suggest that significant genetic events outside of the spike region have contributed to the evolution of PEDV.

1 October 2019 in Cell Reports
Verified
Journal Article
Open access
DSDaniel Salamango
Daniel Salamango
TITerumasa Ikeda
Terumasa Ikeda
SMSeyed Arad Moghadasi
Seyed Arad Moghadasi
JWJiayi Wang
Jiayi Wang
JMJennifer L. McCann
Jennifer L. McCann
RHReuben Harris
Reuben Harris
HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A-E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.

1 December 2019 in Journal of Virology
Verified
Journal Article
Closed access
ACAdam Z. Cheng
Adam Z. Cheng
SMSofia Moraes
Sofia Moraes
CAClaire Attarian
Claire Attarian
JYJaime Yockteng-Melgar
Jaime Yockteng-Melgar
MJMatthew C. Jarvis
Matthew C. Jarvis
RHReuben Harris
Reuben Harris
The APOBEC3 family of DNA cytosine deaminases constitutes a vital innate immune defense against a range of different viruses. A novel counterrestriction mechanism has recently been uncovered for the gammaherpesvirus EBV, in which a subunit of the viral protein known to produce DNA building blocks (ribonucleotide reductase) causes A3B to relocalize from the nucleus to the cytosol. Here, we extend these observations with A3B to include a closely related gammaherpesvirus, KSHV, and a more distantly related alphaherpesvirus, HSV-1. These different viral ribonucleotide reductases also caused relocalization of A3A, which is 92% identical to A3B. These studies are important because they suggest a conserved mechanism of APOBEC3 evasion by large double-stranded DNA herpesviruses. Strategies to block this host-pathogen interaction may be effective for treating infections caused by these herpesviruses.

14 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASArtur A. Serebrenik
Artur A. Serebrenik
GSGabriel J. Starrett
Gabriel J. Starrett
SLSterre Leenen
Sterre Leenen
MJMatthew C. Jarvis
Matthew C. Jarvis
NSNadine M. Shaban
Nadine M. Shaban
RHReuben Harris
Reuben Harris
Human cells express up to 9 active DNA cytosine deaminases with functions in adaptive and innate immunity. Many cancers manifest an APOBEC mutation signature and APOBEC3B (A3B) is likely the main enzyme responsible. Although significant numbers of APOBEC signature mutations accumulate in tumor genomes, the majority of APOBEC-catalyzed uracil lesions are probably counteracted in an error-free manner by the uracil base excision repair pathway. Here, we show that A3B-expressing cells can be selectively killed by inhibiting uracil DNA glycosylase 2 (UNG) and that this synthetic lethal phenotype requires functional mismatch repair (MMR) proteins and p53. UNG knockout human 293 and MCF10A cells elicit an A3B-dependent death. This synthetic lethal phenotype is dependent on A3B catalytic activity and reversible by UNG complementation. A3B expression in UNG-null cells causes a buildup of genomic uracil, and the ensuing lethality requires processing of uracil lesions (likely U/G mispairs) by MSH2 and MLH1 (likely noncanonical MMR). Cancer cells expressing high levels of endogenous A3B and functional p53 can also be killed by expressing an UNG inhibitor. Taken together, UNG-initiated base excision repair is a major mechanism counteracting genomic mutagenesis by A3B, and blocking UNG is a potential strategy for inducing the selective death of tumors. Significance APOBEC3B (A3B) is overexpressed in multiple tumor types and a major source of mutation by converting DNA cytosines to uracils. A3B-positive tumors are often more heterogenous and result in poor clinical outcomes. We show that a proportion of A3B-catalyzed uracil lesions is repaired by uracil DNA glycosylase 2 (UNG)-driven base excision repair and that rendering cells UNG-defective leads to cytotoxicity. This cell death mechanism requires uracil processing by mismatch repair proteins and functional p53. Our results indicate that UNG inhibition could be a strategy to kill a subset of A3B-positive tumors.